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Abstract
Background: Artesunate/sulphadoxine-pyrimethamine (AS/SP) has been the first-line treatment for falciparum
malaria in Sudan since 2004. The impact of this combination on anti-malarial resistance-associated molecular
markers has not been investigated. In this study, an evaluation of the efficacy and prevalence of drug resistance
alleles (pfcrt, pfmdr1, pfdhfr and pfdhps) eight years after the adoption of AS/SP in eastern Sudan is reported.
Methods: A 28-day follow-up efficacy trial of AS/SP was conducted in eastern Sudan during the 2012 transmission
season. Blood smears were collected from patients on days 0, 1, 2, 3, 7, 14, 21 and 28. Blood spots on filter paper
were obtained pre-treatment and on the day the patient was parasite positive by microscopy. Genotyping of alleles
was performed by qPCR (pfcrt 72–76 and pfmdr1 copy number) and direct sequencing of pfmdr1, pfdhfr and pfdhps.
Results: Sixty-three patients out of 68 (93%) completed the 28-day follow-up, adequate clinical, and parasitological
response occurred in 90.5% and 85.3% of the patients in the per-protocol and intent-to-treat analyses, respectively.
PCR corrected per-protocol efficacy was 93.7%. The enrolment prevalence of pfcrt-CVMNK was 30.2% and pfmdr1-
N86 was 40.3%. The pfmdr1 haplotype NFD occurred in 32.8% of pre-treatment samples and was significantly
higher than previous reports (Fisher’s exact p = 0.0001). The pfdhfr-51I/108N combination occurred in all sequenced
isolates and 59R was observed in a single individual. pfdhps substitutions 436A, 437G, 540E, 581G and 613S were
observed at 7.8, 77.3, 76.9%, 33.8% and 0.0%, respectively. Treatment failures were associated with the pfdhps
haplotype SGEGA at these five codons (OR 7.3; 95% CI 0.65 - 368; p = 0.048).
Conclusion: The decrease of CQR associated genotypes reflects the formal policy of complete removal of CQ in
Sudan. However, the frequency of markers associated with SP failure is increasing in this study area and may be
contributing to the treatment efficacy falling below 90%. Further monitoring of AS/SP efficacy and of post-
treatment selection of pfdhfr and pfdhps alleles in vivo is required to inform future treatment guidelines.
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Background
Malaria continues to affect over two million people
worldwide with more than 600,000 reported deaths in
2010, most of these in sub-Saharan Africa [1]. There are
increasing efforts to control, eliminate or eradicate mal-
aria in many countries [2], however these are hindered
by ineffective treatment and vector control strategies
that cannot be sustained in economically disadvanta-
geous countries.
Malaria in Sudan causes morbidities and mortality
among all age groups and was responsible for more than
95,000 hospital admissions in 2011 [3]. Plasmodium
falciparum causes over 95% of malaria infections and
drug resistance to CQ and SP is well established [4-7].
The wide-scale deployment of artemisinin combination
therapy (ACT) across malaria-endemic zones is inten-
ded to counteract the emergence and spread of resist-
ance [8]. Artesunate-sulphadoxine/pyrimethamine (AS/
SP) and artemether-lumefantrine (AL) became the first-
and second-line of treatment, respectively, for uncom-
plicated P. falciparum malaria in 2004 [9]. Recently, the
efficacy of AS/SP has been questioned among practicing
physicians with some patients returning with recurring
infections. The in vivo efficacy of SP in eastern Sudan
was reported at 82% [10], similar to Tanzania (86%) [11]
and high levels of resistance to SP in East Africa [12,13]
may render the short half-life artesunate partner unpro-
tected. Furthermore the emergence of slow clearing par-
asites following artesunate treatment in South East Asia
[14,15] has prompted closer monitoring of the efficacy
of ACT and necessitated extensive research on molecu-
lar markers of resistance to artemisinins and partner
drugs.
Specific haplotypes of the pfcrt gene at positions 72 –
76 (CVMNK; wild haplotype and CVIET; mutant Asian/
African haplotype; mutant SVMNT South American
haplotype) are well-established markers for resistance to
CQ [16,17]. In eastern Sudan the prevalence of the pfcrt-
76T increased from 54% in the early 1990’s [18,19] to
more than 90% in the 2000’s [7,20,21]. However, the
pfcrt-76K allele has returned to high prevalence in parts
of Africa where CQ was discontinued, such as Malawi
[22,23], Kenya [24,25], Senegal, [26] Tanzania [27,28]
and Mozambique [29].
Pfmdr1 haplotypes N86, 184F and 1246D have been se-
lected by artemether-lumefantrine in eastern Sudan [30]
as well as several parts of Africa [31-34]. These haplotypes
were also found to increase the risk of treatment failure
with AL [35]. Amplification of pfmdr1 which is associated
with decreased sensitivity to artemisinins in South East
Asia [36,37] has recently been observed in eastern Sudan
[30] and in neighbouring east African countries [38,39].
Therefore, pfmdr1 may continue to be under the influence
of ACT currently employed in Sudan.
Resistance to pyrimethamine is due to a set of sequen-
tial mutations in the dihydrofolate reductase gene (dhfr)
[40,41]. The serine to asparagine at position 108 is es-
sential with additional mutations at positions N51I,
C59R and I164L leading to higher resistance levels
[42,43]. Mutations in the pfdhps gene (S436A, G437A,
K540E, A581G and A613S) encoding the target enzyme
for sulphadoxine are also predictors of treatment failure
in vivo [44]. It has been recommended that SP should
be discontinued in areas where the prevalence of the
pfdhps-540E allele is more than 50% [12]. In eastern
Sudan, the prevalence of the pfdhfr CICNI haplotype at
codons 50, 51, 59, 108 and 164 has been reported at 90%
[20]. The pfdhps haplotype SGEAA (436/437/540/581/
613) was higher than 80% in the current study area prior
to the introduction of AS/SP [20]. These two alleles may
be maintained in the population by the strong selection
pressure imposed by SP as an ACT component.
In this study, the prevalence of molecular markers in
four genes (pfcrt, pfmdr1, pfdhfr and pfdhps) associated
with drug resistance following the wide scale deploy-
ment of AS/SP in eastern Sudan is investigated and an
updated clinical efficacy of AS/SP is reported.
Methods
Patients enrolment
Patients were recruited between January and March 2012
at Fatima Eldiaaig Health Centre in Kassala City in eastern
Sudan, which is characterized by moderate perennial mal-
aria transmission with a peak in January [45]. Febrile pa-
tients (auxiliary temperature of ≥37.5°C) from all age
groups with microscopically confirmed uncomplicated P.
falciparum mono-infection and a parasite count of a mini-
mum of 1,000 a sexual parasites/μl were asked to partici-
pate and those who consented were enrolled. Patients with
concomitant illnesses and pregnant women were excluded
from the study. A structured questionnaire for socio- de-
mographic information and medical history was completed
for each patient by a physician. The study was performed
as per the WHO guidelines for anti-malarial drug efficacy
surveillance methods [46].
Sample collection and laboratory diagnosis
Finger prick samples were taken from all participants,
thick smears were prepared and stained with 10X
Giemsa stain and slides were read under a 100X oil im-
mersion field. Parasite density was obtained by counting
asexual parasites against 200 leucocytes and parasite
density was calculated assuming an average of 6,000
leucocytes/μl. Slides were read by two experienced mi-
croscopists: a slide was considered negative if no para-
sites were detected in 100 high powerfields. Blood spots
were collected on Whatman® No. 3 filter paper, air dried
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and stored in self-sealing bags for DNA analysis pre-
treatment and on the day of treatment failure.
Treatment and follow up
All participants were given, under observation, arte-
sunate/sulphadoxine-pyrimethamine(Artecospe, Guilin
pharmaceutical, China) comprising 4 mg/kg artesunate
on days 0–2 as a single daily dose and a single dose of
SP (25 mg/kg sulphadoxine, 1.25 mg/kg pyrimetha-
mine) on day 0. For children the dose was adjusted by
weight and the tablets were dissolved in water for oral
administration. A full dose of the drug was repeated in
case of vomiting after 60 minutes and half the dose was
repeated if the patient vomited between 30 to 60 minutes
after drug administration.
Patients were asked to return to the health centre on
days 1, 2, 3, 7, 14, 21 and 28 or if they remained unwell,
on each visit axillary temperature was measured and a
blood smear was taken. Patients were asked about any
adverse effects of the drugs such as nausea, vomiting,
abdominal pain, itching and rashes: these symptoms
were considered drug induced if they were not reported
on enrolment.
Patients who remained microscopy negative for asexual
parasitaemia of P. falciparum throughout the follow up
period were considered to have achieved adequate clinical
and parasitological response (ACPR). Treatment failure
was classified as early treatment failure (ETF), late para-
sitological failure (LPF) or late clinical failure (LCF) ac-
cording to the WHO guidelines [46]. Those who failed
treatment were given AL (Coartem®) as per the Sudanese
National Malaria Control Programme guidelines.
DNA extraction and loci detection
Parasite DNA was extracted from dried filter paper in 96-
deep-well plates by the Chelex® extraction method [47]
with modifications for 96-well plates [34]. The pfcrt loci at
codons 72 – 76 were detected by a Taqman assay as de-
scribed previously [7]. Briefly, 5 μl of DNA were added to
the master mix containing 0.3 μM of primers CRTD1 and
CRTD2 [48] and 0.1 μM of each probe (crt76-CVMNK,
crt76-CVIET and crt76-SVMNT).
Regions of pfmdr1 encompassing polymorphisms at po-
sitions N86Y, Y184F, C1034S, D1042N and D1246Y were
amplified with previously reported primers [34]. Poly-
morphic sites in pfdhfr N51I, C59R, S108N, I164L, pfdhps
A436, A437G, K540E, A581G and A613S were amplified
as previously described [49] and directly sequenced.
Amplification of the pfmdr1 gene was investigated by
a qPCR assay as previously described [50] employing the
Taqman® Universal Mastermix. DNA from clones 3D7
and Dd2 were employed as controls for single and mul-
tiple copy number, respectively. Each sample and control
was run in triplicate.
Msp1 and msp2 polymorphic markers were amplified
as described previously [51] to confirm the origin of re-
curring parasites in those patients that were microscop-
ically positive during the follow up.
Ethical considerations
The study received ethical clearance from the Health Re-
search Board at Ministry of Health, Kassala State. Writ-
ten informed consent was obtained from each patient or
child guardian.
Statistical analysis
The intention-to-treat analysis included all enrolled pa-
tients who met the inclusion criteria and took at least one
full dose of AS/SP. Patients lost to follow-up or withdrawn
from the study were considered to be treatment failures.
The per protocol (PP) analysis included data for patients
who had completed the follow-up. Those patients lost to
the follow-up or who were withdrawn because of protocol
violations were excluded from the PP analysis. Clinical
data were entered in MS-Excel and analysed in SPSS soft-
ware (SPSS Inc., Chicago, IL, USA). The means (age,
weight, temperature and parasite count) were calculated
for all patients. The difference in frequency of haplotypes
observed in 2003 [20,52], 2006 [30], and in this study were
analysed by Fisher’s exact test (STATA Statistical Software:
Release 8.1, 2003, Stata Corp., College Station, TX). Odds
ratios were calculated where appropriate. The difference
was assumed significant if the p-value ≤ 0.05.
Results
A total of 453 patients who came to the clinic with fever
and reporting any malaria-like symptoms were screened
for P. falciparum infection. Sixty-eight patients fulfilled
the enrolment criteria and consented to participate in
the study, sixty-three (92.6%) of whom completed 28-
days of follow up. Patient age, weight, temperature, para-
site density and gender are summarized in Table 1.
Mean time to resolving clinical symptoms such as fever
(axillary temperature above 37°C), malaise and nausea
was 2.7 days (range 2 – 7 days) and was not a risk for
failing treatment.
On day 1; 12.7% (8/63) patients were febrile and 20.6%
(13/63) patients were parasitaemic. However, all patients
cleared their parasitaemia by day 3 with one patient
Table 1 Characteristics of study participants
Variable Mean [range]
Age (years) 25.8 [2 – 70]
Weight (Kg) 44.9 [6 – 104]
Temperature °C 38.3 [37.5 – 40.7]
Geometric mean parasite density parasites/μl 4167.1 [1,080 – 200,000]
Sex: female (%) male (%) 44.4% 55. 6%
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remaining febrile (temperature 38°C). Gametocytaemia
was observed in 3.2% (2/63) of patients at recruitment.
Adverse effects of the drugs such as nausea, headache,
cough, dizziness, abdominal pain and diarrhoea were
reported in 34.9% (22/63) of patients between day 19
and 28. In the intent-to-treat analysis where all patients
who were enrolled were included in the analysis, the ef-
ficacy of AS/SP was 85.3%. While in the per-protocol
analysis the efficacy was 90.5%. Two patients failed treat-
ment at day 21, one failed treatment at day 26 and two
failed treatment at day 28. The PCR corrected efficacy
was 93.6% where 4/5 of treatment failures were classified
as recrudescing parasites. Factors such as pre-treatment
parasite density, axillary temperature and age did
not differ significantly between those who failed treat-
ment and those who were successfully treated.
Expansion of wild type pfcrt and pfmdr1 haplotypes
following withdrawal of CQ
The wild type pfcrt haplotype CVMNK has significantly
recovered from 10% in 2003 [52] to 30.2% (Fishers exact
p < 0.001) in this study. . The N86 allele has also in-
creased significantly from 14% [52] to 40.3% (Fisher’s
exact p = 0.0059). The prevalence of the wild type Y184
was 15.6% but this was not significantly different from
2006 (Fisher’s exact p = 0.16), while there was a signifi-
cant decrease in mutant 1246Y (Fisher’s exact p = 0.018)
(Table 2) [30]. Pfmdr1 haplotypes at positions 86/184/
1246 were less diverse than 2006. The major pfmdr1
haplotype in this study was YFD observed in 51.6% of
pre-treatment samples. NFD has significantly increased
in prevalence from 5.6% in 2006 to 32.8% in 2012
(Fishers exact p = 0.0001) (Figure 1). The NFD haplotype
was detected in 3/5 post-treatment samples and 2 sam-
ples were YFD. All the isolates analysed in this study car-
ried the wild type alleles at positions S1034 and N1042
and a single copy of the pfmdr1 gene (mean 1.2; range
0.6 to 1.5).
Changes in antifolate resistance markers
For the pfdhfr gene a total of 59 samples were successfully
sequenced for positions 50 to 164. All of which carried
the 51I and 108N mutant alleles. This is a significant
increase from previous years (Fisher’s exact p = 0.041). One
sample (1.7%) harboured the mutant 59R and all of the
samples were wild-type at position 164. Thus the predom-
inant haplotype for pfdhfr in eastern Sudan is 51I/C59/
108N.
A total of 65 pre-treatment samples were successfully ge-
notyped at the pfdhps positions 430 to 613. A novel poly-
morphism at position L516F was detected in one sample.
The prevalence of the 581G allele significantly increased
since the 2003 study from 14% to 33.8% (Fisher’s exact p =
0.0005), while the 437G decreased slightly from 89% to 77%
(Fisher’s exact p = 0.0134) [20]. In pre-treatment samples,
the 581G allele was strongly linked to the 540E (p = 0.0009)
and the 437G (p = 0.0018). The prevalence of S436A,
A437G, L516F, K540E and A613S are listed in Table 3.
Pfdhps sequencing was successful for all five treatment
failures, collected at day 21 (2), day 26 (1) and day 28
(2). The haplotype across the five polymorphic codons
436, 437, 540, 581 and 613 are shown for these two
groups in Figure 2. Whereas all five samples collected at
the time of treatment failure carried the 540E substitu-
tion as expected, all of them also carried the 437G and
581G. Thus, the pfdhps haplotype SGEGA, at these five
polymorphic positions, was significantly more common
in parasites detected after treatment (OR 7.3; 95% CI
0.65 - 368; p = 0.048) whether these parasites were re-
crudescing or re-infecting parasites. Further, the pres-
ence of this pfdhps genotype in the pre-treatment
Table 2 Changes in pre-treatment frequencies of pfcrt
and pfmdr1 haplotypes between 2003 and 2012 in
eastern Sudan
pfcrt/pfmdr1
allele
2003 % 2006 % 2012 % p-value 2003/2006
CVIET 93[20] 90[52] 74.6 0.000/0.080
CVMNK 10[52] 30.2 0.010
CVMNK/CVIET 24[52] 4.8 0.012
N86 14[52] 12.1[30] 40.3 0.006/0.0001
86Y 84[52] 85[30] 55.2 0.006/0.000
86 N/Y 2[52] 3[30] 4.5 0.629/0.691
184F 74[30] 80.6 0.165
184 Y/F 0[30] 4.5 0.074
1246Y 6[30] 0.0 0.755
1246 D/Y 3[30] 0.0 0.270
p-values were calculated by comparing actual number of patients displaying
each genotype from previous studies performed in Gedarif in 2003 [20,52] and
Gedarif and Kassala 2006 [30]) and the current study (Kassala) by Fishers
exact test.
Figure 1 Difference in proportions of pfmdr1 haplotypes in
eastern Sudan between 2006 and 2012.
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infection was a significant risk factor for later treatment
failure (relative risk 7.3, 95% CI 0.87 - 61.6; p = 0.030)
the wide confidence intervals indicate that these obser-
vations need detailed exploration in larger studies.
Discussion
Plasmodium falciparum carrying mutations associated
with drug resistance may be less fit to survive in the ab-
sence of drug pressure. The continuous use of CQ mono-
therapy for decades has lead to almost saturation of the P.
falciparum population in eastern Sudan carrying the mu-
tant pfcrt allele CVIET [7]. Lower drug pressure is
reflected by more wild type pfcrt where transmission is
higher and perennial in central Sudan [53]. Moreover SP
has been used intensively in patients where CQ failed.
This has resulted in the high prevalence of the pfdhfr/
pfdhps mutants (51I/108N/437G/540E) in the late 1990’s
and early 2000’s [18,20,54]. The adoption of AS/SP in
eastern Sudan in 2004 has lead to considerable decrease
in malaria cases in the country [9,55-57]. The clinical effi-
cacy of SP monotherapy in Sudan was approximately 68%
prior to introduction of AS/SP [58]. Therefore, the wis-
dom of deploying this SP containing combination has
been debated among the malaria research community in
Sudan e.g. [59]. The base-line efficacy of AS/SP in eastern
Sudan has been reported between 98 − 100% [56,60-62],
while we have reported a base-line PCR corrected efficacy
of 93% [57]. In the present study the in vivo per-protocol
PCR corrected efficacy of AS/SP over 28 days is 90.5%. All
patients cleared their microscopic parasitaemia by day 3.
Approximately 10% of patients exhibited recrudescing
parasites as confirmed by msp1 and msp2 genotyping dur-
ing the study. It is important to emphasize the relatively
lower transmission season in eastern Sudan compared to
other parts of East Africa. Therefore, to definitely establish
whether these post-treatment infections were true recru-
descence or re-infections requires genotyping at more
polymorphic loci.
A limitation to our data is the lack of parallel PCR
data for days 3 and 14. Sub-microscopic parasites at
these time points have been detected in previous studies
from eastern Sudan [7,30]. Detection of parasites on day
3 is an early warning of slow clearance by artemisinin
derivatives observed in South East Asia [14,15]. A de-
cline in the efficacy of ACT e.g. AL and DHA/PIP has
been reported from Kenya [63]. Sub-microscopic parasit-
aemia has previously been observed following AL treat-
ment in eastern Sudan [30]. While an artemisinin
resistant phenotype has not been reported in Africa [64],
the history of anti-malarial resistance suggests that arte-
misinin resistance is likely to spread to East Africa des-
pite the global efforts in its containment.
In the present study, the prevalence of molecular
markers eight years after the adoption of ACT is com-
pared to previous reports from the same study area of
eastern Sudan. In this area IPTp is recommended for all
pregnant women, as in other parts of Sudan.
The prevalence of a double mutant pfdhfr allele (51I/
108N) has reached 100%, which clearly demonstrates the
effect of drug pressure on this locus. The observation
that contrasts with other African countries is the slow
evolution of pfdhfr in this region where the double mu-
tant 51–108 allele has widely spread while the wild type
C59 has been maintained. However it is in agreement
with a recent report from Yemen [65]. The 59R is asso-
ciated with increased resistance to pyrimethamine,
therefore absence of this mutation may be a good indica-
tor for the in vivo efficacy of SP in this region. The
pfdhfr 59R has been previously reported at low fre-
quency in Khartoum, central Sudan in 1996/1997 [66]
and Nuba mountains in western Sudan in 2003 [67].
Table 3 Prevalence of pfdhfr and pfdhps alleles in Sudan
before and after adoption of ACT
pfdhfr/pfdhps allele 2003 % 2012 % p-value [20,52]
51I/108N 90[20] 84[52] 100 0.004/0.001
59R 1[20] 0[52] 1.7 0.477/1.000
436A 0[52] 7.8 0.069
437G 89[20] 0[52] 77.3 0.013/0.000
516F 1.7*
K540 20[52] 21.5 0.000
540E 79[20] 76.9 0.860
540K/E 80[52] 1.5 0.000
581G 14[20] 10[52] 33.8 0.001/0.007
581A/G 10[52] 1.5 0.202
A613 100[20,52] 100 1.000
p-values were calculated by comparing actual number of patients displaying
each genotype from previous studies performed in Gedarif in 2003 [20,52] and
Gedarif and Kassala, 2006 [30]) and the current study (Kassala) by Fishers exact
test. * not previously reported.
Figure 2 Proportions of pfdhps haplotypes before and after
treatment with AS/SP in Kassala State 2012.
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However the 51I/108N haplotype has been observed at
low frequencies in Kenya and Cameroon in the early
2000s where the pfdhfr-51I/59R/108N haplotype cur-
rently predominates [68,69]. These studies employed
microsatellite markers which demonstrated the diver-
gence of origin of the double (51I/108N) and triple mu-
tants within the same geographic location. An earlier
study in eastern Sudan has shown that microsatellites
around pfdhfr were stable over four consecutive seasons
[18]. Thus, the pfdhfr allele 51I/108N may have been
imported into this area earlier and has been maintained
within a limited parasite population in a low transmis-
sion area of eastern Sudan. However, it would be of
interest to examine pfdhfr sequences and microsatellite
markers from other regions of Sudan with different
transmission intensities to test this hypothesis.
Interestingly in this study, a small decrease in pfdhps-
437G (Fisher’s exact p = 0.0134) is observed compared to
previous reports [20]. The 581G allele has significantly in-
creased to 33% and has previously been associated with SP
failure in eastern Sudan [20] emphasizing the importance
of close monitoring of the parasite population in this re-
gion. For the first time, a particular pfdhps allele, SGEGA,
is significantly associated with treatment failure in patients
receiving AS/SP for clinical malaria. However of 23 pre-
treatment infections harbouring SGEGA, only four recru-
desced. The increase of SGEGA has been previously
reported from Tanzania in cross sectional surveys follow-
ing several years of SP use [27]. The potential of this
haplotype as a single marker of drug efficacy for this anti-
malarial combination should be further investigated.
As previously reported from other African countries
[22,24,28], there is a significant decrease in CQR associ-
ated genotypes pfcrt-76T/pfmdr1-86Y. Wild type geno-
types at these two loci have significantly recovered,
which provides supporting evidence that CQ use has
been successfully reduced [70]. Interestingly the multiple
copy pfmdr1 genotype previously reported from eastern
Sudan [30] was not observed here. This genotype is as-
sociated with resistance to mefloquine (MQ) in South
East Asia [50] and may not spread in the absence of MQ
pressure, which is the case in Sudan. In addition
pfmdr1amplification has failed to be established and
spread in Africa, possibly due to lack of the use of MQ
across the continent.
In Sudan SP is recommended for iPTp and the avai-
lability of SP as an over-the-counter drug maintains the
pressure on the parasite population. The efficacy of AS/SP
is reaching the current threshold for anti-malarial policy
change of 90%. Continuous use of SP as a partner to
artesunate may be the cause of declined AS/P efficacy. In
addition discontinuation of SP in areas where the population
prevalence of pfdhps-540E is above 50% is also recommended
[12,71]. Monitoring of SP resistance associated loci, and in
particular the SGEGA pfdhps haplotype identified here, is
required to provide informed treatment guidelines in the
near future. In addition the emergence of slow parasite
clearance in South East Asia warrants close monitoring of
the efficacy of ACT and molecular markers associated
with resistance to partner drugs.
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